LegalJul 16, 2026, 04:35 PM
ANI Pharmaceuticals to appeal court ruling in CG Oncology dispute
AI Summary
ANI Pharmaceuticals announced that a trial court denied its post-trial motions for a new trial and judgment as a matter of law regarding its dispute with CG Oncology. The company intends to appeal these rulings to the Delaware Supreme Court. ANI seeks to recover the value of assets it sold to CG Oncology in 2010 and a 5% running royalty on future worldwide sales of cretostimogene grenadenorepvec.
Key Highlights
- Trial court denied ANI's post-trial motions for a new trial and judgment as a matter of law.
- ANI intends to appeal the rulings to the Delaware Supreme Court.
- Company seeks to recover the value of assets sold to CG Oncology in 2010.
- ANI aims to receive a 5% running royalty on future worldwide sales of cretostimogene grenadenorepvec.
Price Impact
More from ANIP